Cilastatin / Imipenem Dosage
Medically reviewed by Drugs.com. Last updated on Sep 7, 2023.
Applies to the following strengths: 250 mg-250 mg; 500 mg-500 mg; 750 mg-750 mg
Usual Adult Dose for:
- Bacteremia
- Endocarditis
- Intraabdominal Infection
- Joint Infection
- Osteomyelitis
- Pneumonia
- Pyelonephritis
- Septicemia
- Bacterial Infection
- Urinary Tract Infection
- Bronchitis
- Pelvic Infections
- Endometritis
- Skin or Soft Tissue Infection
- Skin and Structure Infection
- Nosocomial Pneumonia
- Peritonitis
Usual Pediatric Dose for:
- Bacteremia
- Endocarditis
- Intraabdominal Infection
- Joint Infection
- Osteomyelitis
- Pneumonia
- Pyelonephritis
- Septicemia
- Bacterial Infection
- Urinary Tract Infection
- Skin and Structure Infection
- Bronchitis
- Pelvic Infections
- Endometritis
- Peritonitis
Additional dosage information:
Usual Adult Dose for Bacteremia
If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours
If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa
Usual Adult Dose for Endocarditis
If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours
If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa
Usual Adult Dose for Intraabdominal Infection
If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours
If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa
Usual Adult Dose for Joint Infection
If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours
If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa
Usual Adult Dose for Osteomyelitis
If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours
If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa
Usual Adult Dose for Pneumonia
If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours
If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa
Usual Adult Dose for Pyelonephritis
If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours
If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa
Usual Adult Dose for Septicemia
If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours
If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa
Usual Adult Dose for Bacterial Infection
If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours
If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa
Usual Adult Dose for Urinary Tract Infection
If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours
If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa
Usual Adult Dose for Bronchitis
If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours
If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa
Usual Adult Dose for Pelvic Infections
If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours
If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa
Usual Adult Dose for Endometritis
If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours
If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species (including Bacteroides fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Streptococcus agalactiae (group B streptococci), Enterobacter species, E coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, Morganella morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, Haemophilus influenzae, H parainfluenzae, Klebsiella species, Serratia marcescens
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, Proteus vulgaris, Providencia rettgeri, P aeruginosa
Usual Adult Dose for Skin or Soft Tissue Infection
If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours
If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours
Use: For the treatment of skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
Infectious Diseases Society of America (IDSA) Recommendations:
- Incisional surgical site infection: 500 mg IV every 6 hours
- Necrotizing infections of the skin, fascia, and muscle: 1 g IV every 6 to 8 hours
Comments:
- Recommended as a single-drug regimen for treatment of incisional surgical site infections after intestinal or genitourinary tract surgery
- With other agents, recommended as a preferred regimen for the treatment of necrotizing infections of the skin, fascia, and muscle due to mixed infections
- Current guidelines should be consulted for additional information.
Usual Adult Dose for Skin and Structure Infection
If infection suspected/proven due to susceptible bacterial species: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours
If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours
Use: For the treatment of skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
Infectious Diseases Society of America (IDSA) Recommendations:
- Incisional surgical site infection: 500 mg IV every 6 hours
- Necrotizing infections of the skin, fascia, and muscle: 1 g IV every 6 to 8 hours
Comments:
- Recommended as a single-drug regimen for treatment of incisional surgical site infections after intestinal or genitourinary tract surgery
- With other agents, recommended as a preferred regimen for the treatment of necrotizing infections of the skin, fascia, and muscle due to mixed infections
- Current guidelines should be consulted for additional information.
Usual Adult Dose for Nosocomial Pneumonia
IDSA and American Thoracic Society Recommendations: 500 mg IV every 6 hours
Duration of therapy: 7 days
Comments:
- With other agents, recommended as an empiric treatment regimen for clinically suspected ventilator-associated pneumonia in units where such coverage is appropriate
- Recommended as initial empiric therapy for hospital-acquired pneumonia (non-ventilator-associated pneumonia)
- Suspected ventilator-associated pneumonia: Dose may need to be reduced in patients less than 70 kg to prevent seizures.
- Current guidelines should be consulted for additional information.
Usual Adult Dose for Peritonitis
International Society for Peritoneal Dialysis (ISPD) Recommendations:
Continuous (all exchanges):
- Loading dose: 250 mg/L intraperitoneally
- Maintenance dose: 50 mg/L intraperitoneally
Intermittent (1 exchange daily): 500 mg intraperitoneally in alternate exchange
Comments:
- Recommended for the treatment of peritoneal dialysis (PD)-related peritonitis
- Current guidelines should be consulted for additional information.
Usual Pediatric Dose for Bacteremia
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
Comments:
- Recommended for non-CNS infections
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
- Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa
American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day
Comments:
- Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
- In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
- Current guidelines should be consulted for additional information.
Usual Pediatric Dose for Endocarditis
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
Comments:
- Recommended for non-CNS infections
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
- Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa
American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day
Comments:
- Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
- In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
- Current guidelines should be consulted for additional information.
Usual Pediatric Dose for Intraabdominal Infection
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
Comments:
- Recommended for non-CNS infections
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
- Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa
American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day
Comments:
- Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
- In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
- Current guidelines should be consulted for additional information.
Usual Pediatric Dose for Joint Infection
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
Comments:
- Recommended for non-CNS infections
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
- Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa
American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day
Comments:
- Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
- In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
- Current guidelines should be consulted for additional information.
Usual Pediatric Dose for Osteomyelitis
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
Comments:
- Recommended for non-CNS infections
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
- Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa
American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day
Comments:
- Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
- In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
- Current guidelines should be consulted for additional information.
Usual Pediatric Dose for Pneumonia
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
Comments:
- Recommended for non-CNS infections
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
- Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa
American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day
Comments:
- Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
- In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
- Current guidelines should be consulted for additional information.
Usual Pediatric Dose for Pyelonephritis
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
Comments:
- Recommended for non-CNS infections
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
- Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa
American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day
Comments:
- Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
- In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
- Current guidelines should be consulted for additional information.
Usual Pediatric Dose for Septicemia
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
Comments:
- Recommended for non-CNS infections
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
- Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa
American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day
Comments:
- Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
- In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
- Current guidelines should be consulted for additional information.
Usual Pediatric Dose for Bacterial Infection
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
Comments:
- Recommended for non-CNS infections
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
- Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa
American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day
Comments:
- Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
- In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
- Current guidelines should be consulted for additional information.
Usual Pediatric Dose for Urinary Tract Infection
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
Comments:
- Recommended for non-CNS infections
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
- Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa
American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day
Comments:
- Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
- In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
- Current guidelines should be consulted for additional information.
Usual Pediatric Dose for Skin and Structure Infection
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
Comments:
- Recommended for non-CNS infections
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
- Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa
American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day
Comments:
- Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
- In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
- Current guidelines should be consulted for additional information.
Usual Pediatric Dose for Bronchitis
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
Comments:
- Recommended for non-CNS infections
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
- Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa
American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day
Comments:
- Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
- In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
- Current guidelines should be consulted for additional information.
Usual Pediatric Dose for Pelvic Infections
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
Comments:
- Recommended for non-CNS infections
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
- Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa
American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day
Comments:
- Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
- In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
- Current guidelines should be consulted for additional information.
Usual Pediatric Dose for Endometritis
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
Comments:
- Recommended for non-CNS infections
Uses: For the treatment of:
- Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
- Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
- Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
- Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
- Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
- Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
- Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
- Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa
American Academy of Pediatrics Recommendations:
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day
Comments:
- Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
- In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
- Current guidelines should be consulted for additional information.
Usual Pediatric Dose for Peritonitis
ISPD Recommendations:
Continuous:
- Loading dose: 250 mg/L intraperitoneally
- Maintenance dose: 50 mg/L intraperitoneally
Comments:
- Recommended for the treatment of PD-related peritonitis
- Current guidelines should be consulted for additional information.
Renal Dose Adjustments
Adult patients:
If infection suspected/proven due to susceptible bacterial species:
- CrCl at least 90 mL/min: 500 mg (imipenem component) IV every 6 hours OR 1 g (imipenem component) IV every 8 hours
- CrCl 60 to less than 90 mL/min: 400 mg (imipenem component) IV every 6 hours OR 500 mg (imipenem component) IV every 6 hours
- CrCl 30 to less than 60 mL/min: 300 mg (imipenem component) IV every 6 hours OR 500 mg (imipenem component) IV every 8 hours
- CrCl 15 to less than 30 mL/min: 200 mg (imipenem component) IV every 6 hours OR 500 mg (imipenem component) IV every 12 hours
- CrCl less than 15 mL/min (not undergoing hemodialysis): Not recommended.
If infection suspected/proven due to bacterial species with intermediate susceptibility:
- CrCl at least 90 mL/min: 1 g (imipenem component) IV every 6 hours
- CrCl 60 to less than 90 mL/min: 750 mg (imipenem component) IV every 8 hours
- CrCl 30 to less than 60 mL/min: 500 mg (imipenem component) IV every 6 hours
- CrCl 15 to less than 30 mL/min: 500 mg (imipenem component) IV every 12 hours
- CrCl less than 15 mL/min (not undergoing hemodialysis): Not recommended.
Pediatric patients less than 30 kg:
- Renal dysfunction: Not recommended.
Comments:
- Adults: The serum creatinine should represent a steady state of renal function; the Cockcroft-Gault method should be used to calculate CrCl.
- Risk of seizures may be increased in adults with CrCl 15 to less than 30 mL/min.
- This drug should not be used in adults with CrCl less than 15 mL/min unless hemodialysis is started within 48 hours.
Liver Dose Adjustments
Data not available
Precautions
CONTRAINDICATIONS:
Hypersensitivity to either active component or to any of the ingredients
Consult WARNINGS section for additional precautions.
Dialysis
Adult patients:
CrCl less than 15 mL/min undergoing hemodialysis:
- If infection suspected/proven due to susceptible bacterial species: 200 mg (imipenem component) IV every 6 hours OR 500 mg (imipenem component) IV every 12 hours
- If infection suspected/proven due to bacterial species with intermediate susceptibility: 500 mg (imipenem component) IV every 12 hours
Peritoneal dialysis: Data not available
Comments:
- Both components are cleared from circulation during hemodialysis; the patient should receive this drug after hemodialysis and at intervals timed from the end of that hemodialysis session.
- Dialysis patients (especially those with background CNS disease) should be carefully monitored; for patients on hemodialysis, this drug is recommended only when the benefit outweighs the potential risk of seizures.
Other Comments
Administration advice:
- For IV infusion only
- Administer doses up to 500 mg by IV infusion over 20 to 30 minutes; administer doses greater than 500 mg by IV infusion over 40 to 60 minutes; may slow rate of infusion in patients with nausea during administration
- Do not administer reconstituted suspension by direct IV infusion.
- Do not exceed the maximum total daily dose of 4 g/day.
Storage requirements:
- Before reconstitution: Store at 20C to 25C (68F to 77F).
- After reconstitution: This drug maintains satisfactory potency for 4 hours at room temperature or for 24 hours refrigerated (5C); do not freeze solution.
Reconstitution/preparation techniques:
- Diluents containing benzyl alcohol should not be used to reconstitute this drug for use in neonates.
- After reconstitution, the resulting suspension should be transferred to an appropriate infusion solution (before IV infusion).
- The manufacturer product information should be consulted.
IV compatibility:
- Compatible diluents: 0.9% Sodium Chloride Injection, 5% Dextrose Injection, 5% Dextrose and 0.9% Sodium Chloride Injection, 5% Dextrose Injection with 0.225% or 0.45% saline solution
- This drug should not be mixed with, or physically added to, other antibacterial agents; this drug may be administered concomitantly with other antibacterial agents (e.g., aminoglycosides).
General:
- Doses represent the quantity of imipenem; an equal amount of cilastatin is also present.
- Adult dose should be based on suspected/confirmed pathogen susceptibility.
- To reduce the development of drug-resistant organisms and maintain effective therapy, this drug should be used only to treat infections proven or strongly suspected to be caused by susceptible bacteria.
- Culture and susceptibility information should be considered when selecting/modifying antibacterial therapy or, if no data are available, local epidemiology and susceptibility patterns may be considered when selecting empiric therapy.
- This drug is not indicated in patients with meningitis (safety and efficacy not established).
- This drug is not recommended in pediatric patients with CNS infections due to risk of seizures.
Monitoring:
- General: Organ system functions, including renal, hepatic, and hematopoietic (periodically during prolonged therapy)
- Hematologic: Hematopoietic function (periodically during prolonged therapy)
- Hepatic: Hepatic function (periodically during prolonged therapy)
- Renal: Renal function (periodically during prolonged therapy)
Patient advice:
- Avoid missing doses and complete the entire course of therapy.
- Contact healthcare provider if severe watery or bloody diarrhea develops.
More about cilastatin / imipenem
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Side effects
- During pregnancy
- Drug class: carbapenems
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
